166 related articles for article (PubMed ID: 36752358)
1. Uptake and Spending on Biosimilar Infliximab and Etanercept After New Start and Switching Policies in Canada: An Interrupted Time Series Analysis.
McClean AR; Cheng L; Bansback N; Clement F; Tadrous M; Harrison M; Law MR
Arthritis Care Res (Hoboken); 2023 Sep; 75(9):2011-2021. PubMed ID: 36752358
[TBL] [Abstract][Full Text] [Related]
2. Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study.
Fisher A; Kim JD; Dormuth CR
CMAJ Open; 2022; 10(1):E109-E118. PubMed ID: 35168933
[TBL] [Abstract][Full Text] [Related]
3. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
Schabert VF; Watson C; Joseph GJ; Iversen P; Burudpakdee C; Harrison DJ
J Manag Care Pharm; 2013 Oct; 19(8):621-30. PubMed ID: 24074008
[TBL] [Abstract][Full Text] [Related]
4. GP2015: An Etanercept Biosimilar.
Deeks ED
BioDrugs; 2017 Dec; 31(6):555-558. PubMed ID: 28940172
[TBL] [Abstract][Full Text] [Related]
5. A rapid monitoring plan following a shift in coverage from brand name to biosimilar drugs for rheumatoid arthritis in British Columbia.
Dormuth CR; Fisher A; Carney G
Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):796-802. PubMed ID: 31914214
[TBL] [Abstract][Full Text] [Related]
6. The nocebo effect challenges the non-medical infliximab switch in practice.
Boone NW; Liu L; Romberg-Camps MJ; Duijsens L; Houwen C; van der Kuy PHM; Janknegt R; Peeters R; Landewé RBM; Winkens B; van Bodegraven AA
Eur J Clin Pharmacol; 2018 May; 74(5):655-661. PubMed ID: 29368188
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis.
Ditto MC; Parisi S; Priora M; Sanna S; Peroni CL; Laganà A; D'Avolio A; Fusaro E
Sci Rep; 2020 Sep; 10(1):16178. PubMed ID: 32999362
[TBL] [Abstract][Full Text] [Related]
8. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
Aladul MI; Fitzpatrick RW; Chapman SR
BioDrugs; 2017 Dec; 31(6):533-544. PubMed ID: 29127626
[TBL] [Abstract][Full Text] [Related]
9. Rapid monitoring of health services utilization following a shift in coverage from brand name to biosimilar drugs in British Columbia-An interim report.
Fisher A; Kim JD; Dormuth CR
Pharmacoepidemiol Drug Saf; 2020 Jul; 29(7):803-810. PubMed ID: 32463156
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review.
Strand V; Balsa A; Al-Saleh J; Barile-Fabris L; Horiuchi T; Takeuchi T; Lula S; Hawes C; Kola B; Marshall L
BioDrugs; 2017 Aug; 31(4):299-316. PubMed ID: 28612180
[TBL] [Abstract][Full Text] [Related]
11. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
12. Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada.
Fenna J; McCormack D; Kitchen S; Martins D; Gomes T; Tadrous M
J Manag Care Spec Pharm; 2021 Apr; 27(4):444-452. PubMed ID: 33769851
[No Abstract] [Full Text] [Related]
13. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
Lindström U; Glintborg B; Di Giuseppe D; Nordström D; Aarrestad Provan S; Gudbjornsson B; Askling J; Lund Hetland M; Aaltonen K; Krogh NS; Geirsson AJ; Jacobsson LTH
RMD Open; 2019; 5(2):e001079. PubMed ID: 31749988
[TBL] [Abstract][Full Text] [Related]
14. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Phan DB; Bewley AP; Smith CH; Mackenzie T; Griffiths CEM; Lunt M; Warren RB; Yiu ZZN
Br J Dermatol; 2023 Jul; 189(1):62-70. PubMed ID: 37016153
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
[TBL] [Abstract][Full Text] [Related]
16. Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.
Bonafede M; Joseph GJ; Princic N; Harrison DJ
J Med Econ; 2013 Sep; 16(9):1120-8. PubMed ID: 23808901
[TBL] [Abstract][Full Text] [Related]
17. Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry.
Nabi H; Hendricks O; Jensen DV; Loft AG; Pedersen JK; Just SA; Danebod K; Munk HL; Kristensen S; Manilo N; Colic A; Linauskas A; Thygesen PH; Christensen LB; Kalisz MH; Lomborg N; Chrysidis S; Raun JL; Andersen M; Mehnert F; Krogh NS; Hetland ML; Glintborg B
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36418087
[TBL] [Abstract][Full Text] [Related]
18. Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.
Provenzano G; Arcuri C; Miceli MC
Clin Rheumatol; 2021 Jan; 40(1):425-427. PubMed ID: 32776313
[No Abstract] [Full Text] [Related]
19. Brief Report: Utilization of the First Biosimilar Infliximab Since Its Approval in South Korea.
Kim SC; Choi NK; Lee J; Kwon KE; Eddings W; Sung YK; Ji Song H; Kesselheim AS; Solomon DH
Arthritis Rheumatol; 2016 May; 68(5):1076-9. PubMed ID: 26662931
[TBL] [Abstract][Full Text] [Related]
20. Costs associated with non-medical switching from originator to biosimilar etanercept in patients with rheumatoid arthritis in the UK.
Tarallo M; Onishchenko K; Alexopoulos ST
J Med Econ; 2019 Nov; 22(11):1162-1170. PubMed ID: 31373527
[No Abstract] [Full Text] [Related]
[Next] [New Search]
